Home > Name List By e > Eptifibatide

CAS No 188627-80-7 , Eptifibatide

  • Name: Eptifibatide
  • Synonyms: N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2; N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;Eptifibatide; INTEGRELIN;
  • CAS Registry Number:
  • Density: 1.605 g/cm3
  • Refractive index: 1.735
  • Molecular Weight: 831.96
  • InChI: InChI=1/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)
  • Molecular Formula: C35H49N11O9S2
  • Molecular Structure:CAS No:188627-80-7 Eptifibatide

Related products

Search by region :

Select to

188627-80-7 Eptifibatide

  • China GL Biochem (Shanghai) Co., Ltd. [Manufacturers]
  • Tel: +86-21-61263307
  • Fax: +86-21-61263399
  • Address: No.519,ZiYue Road,Zizhu Science Park,Minhang District,Shanghai,China Shanghai,ShanghaiChina
Contact Supplier

188627-80-7 302327 L-CYSTEINAMIDE, N6-(AMINOIMINOMETHYL)-N2-(3-MERCAPTO-1-OXOPROPYL)-L-LYSYLGLYCYL-L-.ALPHA.-ASPARTYL-L-TRYPTOPHYL-L-PROLYL-, CYCLIC (16)-DISULFIDE EPTIFIBATIDE; MAP-HAR-GLY-ASP-TRP-PRO-CYS-NH2 (DISULFIDE BRIDGE, MAP1-CYS6)

  • Germany chemcube UG [Manufacturer]
  • Tel: +49 (22 08) 7 75 04 06
  • Fax: +49 (22 08) 7 75 02 30 /
    +49 (32 12) 1 00 74 76
  • Address: chemcube UG
    Salierweg 1
    53859 Niederkassel
    Germany null,nullGermany
Contact Supplier

188627-80-7 Eptifibatide

  • India Shreeji Pharma International [Manufacturers]
  • Tel: +91-265-3019110
  • Fax: +91-265-2465036
  • Address: FF/10, Narsinghdham Complex, Sangam Chararasta, Harni Road, Vadodara, Gujarat 390018, Vadodara,GujaratIndia
Contact Supplier

188627-80-7 Eptifibatide

Contact Supplier

188627-80-7 Eptifibatide

  • China Facus Pharmaceutical Co., Ltd. [Manufacturers]
  • Tel: +86-(574)-6237-8411
  • Fax: +86-(574)-6237-8410
  • Address: 24Fl, Yuanjing Building, Beilun, Ningbo, Zhejiang 315800, Ningbo,ZhejiangChina
Contact Supplier

188627-80-7 EPTIFIBATIDE

  • United States LGM Pharma [Manufacturer]
  • Tel: 561-981-9994
  • Fax: 561-892-0580
  • Address: 922 Clint Moore Road
    Boca Raton, FL 33487 null,nullUnited States
Contact Supplier

188627-80-7 Eptifibatide

  • United States LKT Laboratories Inc. null
  • Tel: +1 888-558-5227
  • Fax: +1-(651)-644-8424
  • Address: Toll free 888-LKT-LABS St. Paul,nullUnited States
Contact Supplier

188627-80-7 Eptifibatide

  • Denmark kemikalieimport [Manufacturers]
  • Tel: + 45 - 2034 3359
  • Fax: + 45 - 4542 3436
  • Address: Lyngby Hovedgade 61.2800 Lyngby. Lyngby,HovedgadeDenmark
Contact Supplier

188627-80-7 Eptifibatide

  • China Shanghai Richem International Co., Ltd. null
  • Tel: +86-(21)-31263688
  • Fax: +86-(21)-51862199
  • Address: Room 603, Golden Eagle Mansion A, No.1518 Minsheng Road, Pudong, Shanghai 200135, shanghai,shanghaiChina
Contact Supplier

188627-80-7 Eptifibatide

Contact Supplier

Select to

2/4
Previous 1 2 3 4 Next
References of Eptifibatide
Title: Eptifibatide
CAS Registry Number: 188627-80-7
CAS Name: N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1?6)-disulfide
Trademarks: Integrilin (COR)
Molecular Formula: C35H49N11O9S2
Molecular Weight: 831.96
Percent Composition: C 50.53%, H 5.94%, N 18.52%, O 17.31%, S 7.71%
Literature References: Fibrinogen receptor antagonist. Specifically inhibits fibrinogen binding to the platelet integrin GPIIb-IIIa which prevents platelet aggregation and subsequent clot formation. Synthetic, disulfide-linked cyclic heptapeptide based on barbourin, a specific GPIIb-IIIa antagonist isolated from venom of the southeastern pigmy rattlesnake, Sistrurus m. barbouri. Contains the Lys-Gly-Asp (KGD) amino acid sequence, a modification of the Arg-Gly-Asp (RGD) recognition site which appears to confer specificity: R. M. Scarborough et al., J. Biol. Chem. 266, 9359 (1991). Design and structure-activity study of integrin antagonists: eidem, ibid. 268, 1066 (1993). Prepn: R. M. Scarborough et al., US 5686570 (1997 to COR Therapeutics). Pharmacology: F. A. Nicolini et al., Circulation 89, 1802 (1994); K. Uthoff et al., ibid. 90, pt 2, II-269 (1994). Clinical trial in patients undergoing percutaneous cardiovascular intervention: IMPACT-II Investigators, Lancet 349, 1422 (1997). Clinical trial in acute coronary syndromes: PURSUIT Trial Investigators, N. Engl. J. Med. 339, 436 (1998).
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.